Kinnate Biopharma (KNTE)
NASDAQ:KNTE
Holding KNTE?
Track your performance easily

Kinnate Biopharma (KNTE) Income Statement

232 Followers

Kinnate Biopharma Income Statement

Last quarter (Q4 2023), Kinnate Biopharma's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Kinnate Biopharma's net income was $-17.06M. See Kinnate Biopharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
----$ 0.00$ 0.00
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 121.18M$ 121.18M$ 118.52M$ -90.11M$ 36.00M$ 12.01M
Operating Income
$ -121.18M$ -121.18M$ -118.52M$ -90.14M$ -36.00M$ -12.01M
Net Non Operating Interest Income Expense
$ 1.71M---$ 240.00K$ 43.00K
Other Income Expense
$ -6.81M$ -8.53M$ -2.25M$ -348.00K$ -5.00K-
Pretax Income
$ -112.68M$ -112.68M$ -116.32M$ -89.80M$ -35.76M$ -11.97M
Tax Provision
$ -19.00K$ -19.00K$ -21.00K$ -548.00K--
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -112.65M$ -112.65M$ -116.32M$ -89.80M$ -35.76M$ -9.94M
Basic EPS
$ -2.42$ -2.42$ -2.64$ -2.06$ -5.28$ -0.92
Diluted EPS
$ -2.42$ -2.42$ -2.64$ -2.06$ -5.28$ -0.92
Basic Average Shares
$ 186.30M$ 46.58M$ 44.07M$ 43.60M$ 6.77M$ 10.80M
Diluted Average Shares
$ 186.30M$ 46.58M$ 44.07M$ 43.60M$ 6.77M$ 10.80M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 121.18M$ 121.18M$ 118.52M$ -90.11M$ 36.00M$ 12.01M
Net Income From Continuing And Discontinued Operation
$ -112.65M$ -112.65M$ -116.27M$ -89.80M$ -35.76M$ -11.97M
Normalized Income
$ -39.22M$ -110.53M--$ -35.76M$ -11.97M
Interest Expense
------
EBIT
$ -114.39M$ -112.68M$ -116.32M$ -89.80M$ -36.00M$ -12.01M
EBITDA
$ -86.13M$ -116.29M$ -115.04M$ -87.80M$ -35.92M$ -12.01M
Currency in USD

Kinnate Biopharma Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis